PMID- 11739182
OWN - NLM
STAT- MEDLINE
DCOM- 20020111
LR  - 20210216
IS  - 0006-4971 (Print)
IS  - 0006-4971 (Linking)
VI  - 98
IP  - 13
DP  - 2001 Dec 15
TI  - Circulating blood dendritic cells from myeloid leukemia patients display 
      quantitative and cytogenetic abnormalities as well as functional impairment.
PG  - 3750-6
AB  - Dendritic cells (DCs) are responsible for the initiation of immune responses. Two 
      distinct subsets of blood DCs have been characterized thus far. Myeloid DCs 
      (MDCs) and plasmacytoid monocytes (PDCs) were shown to be able to promote 
      polarization of naive T cells. This study shows a dramatic quantitative imbalance 
      in both circulating blood DC subsets in 37 patients with acute myeloid leukemias. 
      Eleven patients (30%) displayed a normal quantitative profile (MDC mean, 0.37% 
      +/- 0.21%; range, 0.01% to 0.78%; PDC mean, 0.21% +/- 0.24%; range, 0.04% to 
      0.62%), whereas 22 (59%) showed a tremendous expansion of MDCs (9 patients: mean, 
      16.76% +/- 14.03%; range, 1.36% to 41%), PDCs (4 patients: mean, 7.28% +/- 6.84%; 
      range, 1% to 14%), or both subsets (9 patients: MDC mean, 10.86% +/- 12.36%; 
      range, 1.02% to 37.1%; PDC mean, 4.25% +/- 3.78%; range, 1.14% to 13.04%). 
      Finally, in 4 patients (11%), no DC subsets were detectable. Both MDC and PDC 
      subsets exhibited the original leukemic chromosomal abnormality. Ex vivo, 
      leukemic PDCs, but not leukemic MDCs, had impaired capacity for maturation and 
      decreased allostimulatory activity. Also, leukemic PDCs were altered in their 
      ability to secrete interferon-alpha. These data provide evidence that DC subsets 
      in vivo may be affected by leukemogenesis and may contribute to leukemia escape 
      from immune control.
FAU - Mohty, M
AU  - Mohty M
AD  - Laboratoire d'Immunologie des Tumeurs, Universite de la Mediterranee, Marseille, 
      France.
FAU - Jarrossay, D
AU  - Jarrossay D
FAU - Lafage-Pochitaloff, M
AU  - Lafage-Pochitaloff M
FAU - Zandotti, C
AU  - Zandotti C
FAU - Briere, F
AU  - Briere F
FAU - de Lamballeri, X N
AU  - de Lamballeri XN
FAU - Isnardon, D
AU  - Isnardon D
FAU - Sainty, D
AU  - Sainty D
FAU - Olive, D
AU  - Olive D
FAU - Gaugler, B
AU  - Gaugler B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Blood
JT  - Blood
JID - 7603509
RN  - 0 (HLA-DR Antigens)
RN  - 0 (Interferon-alpha)
RN  - 0 (Interleukin-3)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 147205-72-9 (CD40 Ligand)
RN  - 207137-56-2 (Interleukin-4)
RN  - 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
SB  - IM
MH  - Animals
MH  - CD40 Ligand/pharmacology
MH  - Cells, Cultured
MH  - *Chromosome Aberrations
MH  - Dendritic Cells/*immunology/ultrastructure
MH  - Flow Cytometry
MH  - Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology
MH  - HLA-DR Antigens/analysis
MH  - Humans
MH  - Immunophenotyping
MH  - Interferon-alpha/biosynthesis/metabolism
MH  - Interleukin-3/pharmacology
MH  - Interleukin-4/pharmacology
MH  - Leukemia, Myeloid, Acute/*blood/*genetics/immunology
MH  - Mice
MH  - Microscopy, Confocal
MH  - T-Lymphocytes/immunology
MH  - Tumor Necrosis Factor-alpha/pharmacology
EDAT- 2001/12/12 10:00
MHDA- 2002/01/12 10:01
CRDT- 2001/12/12 10:00
PHST- 2001/12/12 10:00 [pubmed]
PHST- 2002/01/12 10:01 [medline]
PHST- 2001/12/12 10:00 [entrez]
AID - S0006-4971(20)38470-6 [pii]
AID - 10.1182/blood.v98.13.3750 [doi]
PST - ppublish
SO  - Blood. 2001 Dec 15;98(13):3750-6. doi: 10.1182/blood.v98.13.3750.